THGPSAnnex 1 Questionnaire expert surveyWord下载.docx
《THGPSAnnex 1 Questionnaire expert surveyWord下载.docx》由会员分享,可在线阅读,更多相关《THGPSAnnex 1 Questionnaire expert surveyWord下载.docx(40页珍藏版)》请在冰豆网上搜索。
![THGPSAnnex 1 Questionnaire expert surveyWord下载.docx](https://file1.bdocx.com/fileroot1/2022-11/29/5766ac2b-0a85-454e-850c-f389e6f5424b/5766ac2b-0a85-454e-850c-f389e6f5424b1.gif)
ThisprojectiscommissionedbytheBelgianSciencePolicyandsupportedbytheEuropeanMonitoringCentreforDrugsandDrugAddiction
Introduction
AlthoughBelgiumputsinagreatefforttogaininsightintotheepidemiologicsituationconcerningdruguse(e.g.amongtheschool-goingyouth),Belgiumhasnoextendedresearchtraditioninrelationtotheprevalenceofdruguse.Sofar,theprevalenceofdrugusewithinthegeneralBelgianpopulationhasneverbeenstudied.Theaimofthisresearchisafeasibilitystudyofarepetitivesurveyamongthegeneralpopulation.ThefeasibilitystudyiscommissionedbytheBelgianSciencePolicy
()andcarriedoutbytheInstituteforSocialDrugResearch(Prof.DrTomDecorte,UniversityofGhent)andtheResearchCentreforLongitudinalandLifeCourseStudies(Prof.DrDimitriMortelmans,UniversityofAntwerp).
MostEuropeancountrieshavealreadyconductedoneormoregeneralpopulationsurveys,butthereareimportantintrinsicandmethodological-technicaldifferences.OurresearchcoversadetailedcomparisonofprevalencestudiesinotherEuropeancountries,andincludesalimitedcognitivetestoftheincludeditemswithaviewtotheimplementationofsuchstudyinBelgium.Thefeasibilitystudyiscomposedoffivefoci:
intrinsicfocus(whichconcepts,prevalenceindicators,characteristicsofdruguse,socio-demographiccharacteristics,lifestyleindicatorsandattitudesaretobeincludedintheinstrument),methodologicalfocus(datacollectionmethod,samplesize(sampleframe,overrepresentations,weighting,size),frequencyofthesurvey,etc.),comparativefocus(comparabilitywithnationalandinternationalsurveys),financialfocus(generalcostsinrelationtothechoicesofdatacollectionandlengthofthequestionnaire)andvalorisationfocus(feasibilityanddesirabilityofthedistributionmodeofthefindings).
Inthefirstphaseofthisstudywestudiedtheinternationalrecommendationsregardingmeasurementofdruguseinthegeneralpopulation(EMCDDA,WHO,etc.)Furthermore,ameta-analysisofallexistingprevalencestudiesinEuropeismade.Themeta-analysisofgeneralpopulationsurveyscoversadetailedcomparisonofitemsandquestionmodules,methodsanddesigns,usedinprevalencestudiesinotherEuropeancountries,andtheevaluationofstrengths,restrictions,preconditionsandcostsofthesestudies.Afirstdraftofthismeta-analysisisincludedintheappendix.
AllexpertsresponsiblefornationalpopulationsurveysintheEuropeanUnionareinvitedtocompletethisquestionnaire.Wewouldliketoaskyousomequestionsaboutseveralaspectsofthedesignandtheorganisationofgeneralpopulationsurveysondrugsinyourcountry.Thequestionnaire,developedinclosecooperationwiththeEMCDDA,givesspecialattentiontothelegitimationsforchoicesthatweremadeandto(reasonsfor)deviationsfromEuropeanguidelines,andalsototheimpactofgeneralsocial,culturalandpoliticalpracticesinacountryonthedesignofthestudyandspecificimplicationsandlimitationsofthenationalcontext.Thequestionnairealsofocusesonthecomparabilityandvalorizationofthedata.Nexttogaininginsightintheexperiencesandknow-howofthenationalexperts,youranswersmayhelpustocompleteandup-datetheoverviewofgeneralpopulationssurveyspreviouslymadebytheEMCDDA
().
Asaresult,aproposalofa‘bestfit’designforaBelgianpopulationsurveyondrugusewillbedevelopedandtested.ThismustenableBelgianpolicymakerstodecidewhetherornotandhowtoimplementanationalprevalencestudy.
ThefinalreportwillbeavailableinDutchandEnglishattheendof2008.
Howtofillinthequestionnaire?
Thequestionsarerelatedtothe‘RelazioneAnnualealParlamentosulloStatodelleTossicodipendenzeinItalia’administeredintheyears2001,2003and2005.
Thequestionnairecontainsfourparts.First,somegeneralquestionsareasked,followedbydetailedquestionsaboutintrinsic(A.)andmethodologicalaspects(B.)inordertocompletetheEMCDDAoverview(2001).Thequestionnaireendswithsomequestionsaboutfinancial(C.)andvalorisationaspects(D.).Ittakesabout40minutestocompletethisquestionnaire.
Thequestionnairecanbecompletedintheelectronicversion(recommended)oronaprintedversion.Wekindlyaskyoutoreturnthequestionnairebye-mail,postalserviceorfaxatthelatestbefore19May2008.Thecontactinformationcanbefoundattheendofthisquestionnaire.
Open-endedquestionsmaybeansweredbytyping/writingtheanswerintheprovidedspace.Inaddition,thereareseveralmultiplechoicequestions.Thesequestionscanbeansweredbyclicking/tickingonthebox()besidesthecorrectanswer.
Giventheimportanceofandusefulnessofthismeta-analysisofgeneralpopulationsurveysondrugsformanyexpertsaroundEurope,wehopeforyourparticipationandexpressourgratitudeinadvance.
Yourstruly,
A.Generalquestions
Thefollowingquestionsareonlyrelatedto‘RelazioneAnnualealParlamentosulloStatodelleTossicodipendenzeinItalia’administeredintheyear2005.
1.Thesurveyhasbeencarriedoutat:
Nationallevelonly
Other,pleasespecify
2.Whatwasthetypeofsurvey:
Single:
surveydealtwithdrugs(and/oralcohol,tobaccoandpharmaceuticals)only
Pleasespecifywhyitwasdecidedtodevelopa‘single’survey(andwhy,forexample,thesurveywasnotsetupby‘piggybacking’iftherewasanopportunity).
Multi:
questionsaboutdrugusewerepartofasurveywithawiderscope(piggybacking)
Pleasespecifythetypeofsurvey:
Healthsurvey
Crimesurvey
Whatwas/werethereason(s)forpiggybacking?
Lowercost
Obtaininginformationaboutrelateditems(e.g.health,crime)
Didyourresearchteamevaluatetheimpactofthecontext(e.g.health,crime)onprevalencerates?
Ifyes,couldyouelaborateonthereflectionsmade?
3.Describethemainobjectivesandresearchquestionsthesurveywantedtoanswer:
(a)
(b)
(c)
(d)
4.Whowasthecommissionerofthesurvey(theauthorityorinstitutethatinitiatedandcommissionedthesurvey?
)
Thegovernment(e.g.MinistryofHealth)
Pleasespecifywhichministryordepartment
Anacademicinstitution(e.g.university)
Pleasespecifywhichfacultyorresearchcentre
Aprivate/commercialcompany(e.g.researchagency)
Pleasespecifywhich
5.Whowastheresponsibleagentofthesurvey(theinstituteororganisationthatwasinchargefortheorganisationandanalysisofthesurvey)?
6.Frequencyofthesurvey:
Eachyear(annually)
Everyyears(example:
every2years,3years,4years,etc.)
Everytoyears(example:
every3to4years)
7.Canyouspecifythereason(s)whytheresearchteamchosetoconductthesurveyasfrequentlyasindicatedinthepreviousquestion?
8.Year(s)inwhichasimilarsurveywascarriedoutinyourcountryinthepast:
9.Year(s)inwhichasimilarsurveywillbecarriedoutinthefuture:
10.Whatwasthedatacollectionmethod?
Mail
Telephone
Computer-assistedtelephoneinterviewing(CATI)
Notcomputerassisted
Face-to-face
Computer-assistedpersonalinterviewing(CAPI)
Computer-assistedselfinterviewing(CASI)
Penandpaper
Web-basedsurvey
Otherpleasespecify
11.Howdoyoumotivatethechoiceforthismodeofinterviewing?
12.IsthequestionnairecompatiblewiththerecommendationsoftheEuropeanMonitoringCentreforDrugsandDrugAddiction(EMCDDA)?
No
Yes
HowdoyouassessthecomparabilityofyourquestionnairetotheEuropeanModelQuestionnaire(EMQ)?
FullycomparabletotheEMQ
HighlycomparabletotheEMQ
ModeratelycomparabletotheEMQ
LittlecomparabletotheEMQ
NotcomparabletotheEMQ
PleasespecifytowhatextentthequestionnairedeviatesfromtheEMCDDArecommendations
Concerningtheintrinsicaspects(timeframes:
LTP,LYP,TMP;
frequencyandageoffirstuse;
numberofillicitdrugs;
inclusionofnewproducts;
inclusion/exclusionofadummydrug…)
Pleasespecifyhow:
Pleasespecifywhy:
Concerningthemethodologicalaspects
(TheEMCDDAisnotveryprescriptiveonthispoint.However,thefollowingaspectsarerecommended:
probabilisticsample,regularsurveys,maintainmethodologyandsample,abigenoughsampleandresultsshouldbereproducible…)
13.IsthequestionnairecompatiblewiththerecommendationsoftheWorldHealthOrganization(WHO)?
Pleasespecifytowhatextentthequestionnairedeviatesfromtherecommendations
Concerningtheintrinsicaspects(numberofillicitdrugs,inclusionofnewproducts,inclusion/exclusionofadummydrug…)
Concerningthemethodologicalaspects(samplesize,samplingframe,datacollectionmethod…)
14.HaveyoualsocheckedtheEuropeanSchoolS